| Autor: |
M J, Garrido, P, Berraondo, I F, Trocóniz |
| Rok vydání: |
2016 |
| Předmět: |
|
| Zdroj: |
CPT: Pharmacometrics & Systems Pharmacology |
| ISSN: |
2163-8306 |
| Popis: |
This commentary provides an overview of recent examples of pharmacometrics applied during the clinical development of two antagonists of the programmed death-1 (PD-1) cell surface receptor, pembrolizumab and nivolumab. Despite the remarkable achievements obtained in predicting the correct dosing schedule from different quantitative approaches, data indicated a great degree of heterogeneity in tumor response. To achieve therapeutic goals the search for predictive biomarkers associated with a lack of response and mechanism-based combination studies are warranted. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text